#Antisense And RNAi Therapeutics Market Growth

[industrynewsupdates]

Antisense And RNAi Therapeutics Market: Key Trends and Growth Opportunities

The global antisense and RNAi therapeutics market size is expected to reach USD 14.35 billion by 2030, registering a CAGR of 18.72% from 2024 to 2030, according to a new report by Grand View Research, Inc. Developments in biological vectors & nanotechnology and increased financial help for clinical investigations, including the launch of novel drug molecules, are critical in product development and are driving market expansion.

Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes and companies participating in conducting trials through supporting research institutes are predicted to considerably fuel sector expansion. For instance, in March 2022, Biogen  Inc. and Ionis Pharmaceuticals, Inc. announced outcomes from the Phase 1 study of an investigational antisense oligonucleotide for treating people with amyotrophic lateral sclerosis (ALS). Such increasing clinical trials through industry participants is anticipated to propel the market growth by rising the product launches based on antisense and RNAi therapies.

Antisense and RNAi therapies can be used to treat various disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to regenerate gene expression and regulate protein production, consequently impacting industrial advancement, is receiving much attention. According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome. Such advancements in the industry are expected to propel the demand for RNAi and antisense therapeutics for treating numerous diseases over the forecast period.

Gather more insights about the market drivers, restrains and growth of the Antisense And RNAi Therapeutics Market

Antisense And RNAi Therapeutics Market Report Highlights

• Antisense RNA technology accounted for the largest revenue share in 2023 in the technology segment due to its wide applications in diseases like neurodegenerative and genetic conditions.

• The RNA interference segment is anticipated to witness the fastest growth in technology. This technology is further segmented into siRNA & miRNA. Due to miRNA's important role in sustaining cell identity, it's being employed to understand cancer spread better.

• Based on application, the genetic disease segment's dominance can be attributed to key players' increasing focus on developing novel genetic disease treatments.

• North America accounted for the largest revenue share in the global antisense and RNAi therapeutics market. The region's dominance can be attributed to the presence of several players in the region and their efforts to strengthen their position in the industry.

• Europe is anticipated to register the fastest growth over the forecast period from 2024 to 2030, owing to key companies like Secarna operating and expanding in the region.

Antisense And RNAi Therapeutics Market Segmentation

 Grand View Research has segmented the global antisense and RNAi therapeutics market report based on technology, application, route of administration, and region

Antisense And RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• RNA Interference

• Antisense RNA

Antisense And RNAi Therapeutics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Genetic Disease

• Cancer

• Infectious Disease

• Neurodegenerative Disorders

• Cardiometabolic & Renal Disorders

• Ocular Disorders

• Respiratory Disorders

• Skin Disorders

Antisense And RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Intravenous Injections

• Intrathecal Injections

• Subcutaneous Injections

• Other Delivery Methods

Antisense And RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin  America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

Order a free sample PDF of the Antisense And RNAi Therapeutics Market Intelligence Study, published by Grand View Research.

[credenceresearchdotblog]

The market for nucleic acid and gene therapies in neuromuscular disorders is projected to grow from USD 7,882.25 million in 2024 to USD 16,531.15 million by 2032, with a compound annual growth rate (CAGR) of 9.7%.The field of neuromuscular disorders has witnessed remarkable progress over the past decade, driven by groundbreaking advances in nucleic acid and gene therapies. These innovative treatments hold the potential to address the root causes of genetic neuromuscular conditions, offering hope to millions of patients worldwide. This article delves into the dynamics of the nucleic acid and gene therapies market, exploring its impact on neuromuscular disorders, current trends, and future opportunities.

Browse the full report at https://www.credenceresearch.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-market

Understanding Neuromuscular Disorders

Neuromuscular disorders encompass a range of conditions affecting the nerves that control voluntary muscles, leading to muscle weakness, wasting, or dysfunction. Diseases such as Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS) are some prominent examples. Historically, treatments for these disorders have been limited to symptom management, often with little to no impact on disease progression.

The Role of Nucleic Acid and Gene Therapies

Nucleic acid and gene therapies represent a paradigm shift in the treatment of genetic diseases. By targeting the genetic basis of neuromuscular disorders, these therapies aim to correct, replace, or modulate defective genes or their expression. Key therapeutic approaches include:

Gene Replacement Therapy: This involves delivering a functional copy of a defective gene to restore normal cellular function. An example is Zolgensma, a gene therapy for SMA.

Antisense Oligonucleotides (ASOs): ASOs are synthetic nucleic acid molecules designed to modulate gene expression or splicing. Drugs like Spinraza have revolutionized SMA treatment by enhancing the production of functional survival motor neuron (SMN) protein.

RNA Interference (RNAi): This technique silences specific genes that contribute to disease progression. RNAi-based therapies are being explored for ALS and other conditions.

CRISPR-Cas9 and Gene Editing: Emerging tools like CRISPR offer precise genome editing capabilities, potentially correcting genetic mutations at their source.

Market Growth Drivers

The global market for nucleic acid and gene therapies in neuromuscular disorders has experienced exponential growth, driven by several factors:

Increasing Prevalence of Neuromuscular Disorders: Rising awareness and better diagnostic tools have led to an increase in the identified cases of genetic neuromuscular conditions.

Advancements in Biotechnology: Innovations in vector design, delivery systems, and gene-editing tools have improved the safety and efficacy of therapies.

Regulatory Support: Accelerated approval pathways and orphan drug designations have incentivized research and development efforts in this field.

Strategic Collaborations: Partnerships between pharmaceutical companies, research institutions, and patient advocacy groups have fueled innovation and market expansion.

Challenges in the Market

Despite significant progress, the nucleic acid and gene therapies market faces several challenges:

High Costs: Gene therapies are among the most expensive treatments, with some costing millions of dollars per patient.

Complex Manufacturing Processes: Producing gene therapy products involves sophisticated techniques and stringent quality control measures, contributing to limited scalability.

Delivery Challenges: Efficiently delivering therapies to target tissues like muscles or neurons remains a critical hurdle.

Safety Concerns: Potential immune reactions, off-target effects, and long-term safety issues require careful monitoring.

Emerging Trends

Personalized Medicine: Tailoring therapies based on individual genetic profiles is becoming increasingly feasible, enhancing treatment outcomes.

Non-Viral Delivery Systems: Research into lipid nanoparticles and other non-viral vectors is addressing safety and scalability issues.

Combination Therapies: Integrating nucleic acid therapies with traditional treatments or other advanced modalities offers synergistic benefits.

Global Expansion: Efforts to make these therapies accessible in low- and middle-income countries are gaining momentum, supported by policy initiatives and philanthropic funding.

Future Outlook

The nucleic acid and gene therapies market for neuromuscular disorders is poised for robust growth, with projections estimating a compound annual growth rate (CAGR) exceeding 15% over the next decade. As more therapies gain regulatory approval and manufacturing processes become streamlined, the accessibility and affordability of these treatments are expected to improve.

Key Player Analysis

Biogen

Pfizer, Inc.

Novartis AG

Abbott Laboratories, Inc.

Astellas Pharma, Inc.

Hoffmann-La Roche Ltd.

Sanofi

UCB Pharma

Segments:

Based on Disorder:

Motor Neuron Diseases

Neuropathies

Neuromuscular Junction Disorders

Myopathies including Muscular Dystrophies

Based on Therapy:

AAV Gene Therapy

Postnatal Gene Therapy

Spinal Muscular Atrophy

Based on Application:

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com 

[themarketupdate]

U.S. Laparoscopic Devices Market Unidentified Segments – The Biggest Opportunity Of 2024

Latest added U.S. Laparoscopic Devices Market research study by Archive Market Research offers detailed outlook and elaborates market review till 2030. The market Study is segmented by key regions that are accelerating the marketization. At present, the market players are strategizing and overcoming challenges of current scenario; some of the key players in the study are {Medtronic,Stryker Corporation,Karl Storz SE & CO. Kg,Johnson and Johnson,Olympus Corporation,CONMED Corporation,B. Braun Melsungen AG,The Cooper Companies Inc.,Richard Wolf GmbH,Microline Surgical,BD,Welfare Medical Ltd.,DEAM,Intuitive Surgical,Shenzen Mindray Bio Medical Electronics Co. etc.  Click for Free Sample Report + All Related Graphs & Charts https://archivemarketresearch.com/report/collision-avoidance-sensors-market-1255/sample-report The U.S. Laparoscopic Devices Market size was valued at USD 2.36 billion in 2023 and is projected to reach USD 3.82 billion by 2032, exhibiting a CAGR of 7.13 % during the forecasts period. The latest edition of this report you will be entitled to receive additional chapter / commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation. Each of the segment analysis table for forecast period also high % impact on growth. The Global U.S. Laparoscopic Devices segments and Market Data Break Down are illuminated below: {"Product: Laparoscopes, Energy Systems, Trocars","Application: Bariatric Surgery, Other Surgery","End User: Hospital, Clinic"}

Have Any Questions Regarding Global U.S. Laparoscopic Devices Market Report, Ask Our Experts@ https://archivemarketresearch.com/report/collision-avoidance-sensors-market-1255/enquiry-before-buy This report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market. Thanks for reading this article, we can also provide customized report as per company’s specific needs. You can also get separate chapter wise or region wise report versions including North America, Europe or Asia.

More Reports:

 https://archivemarketresearch.com/reports/us-laparoscopic-devices-market-2286  https://archivemarketresearch.com/reports/antisense-and-rnai-therapeutics-market-2456 Contact US : Craig Francis (PR & Marketing Manager) Archive Market Research Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[laocommunity]

Curing Diseases with the Power of Nucleic Acid-based Drugs: A Promising Growth Forecast for 2023-2029 - KaleidoScot Leads the Way

Curing Diseases with the Power of Nucleic Acid-based Drugs: A Promising Growth Forecast for 2023-2029 - KaleidoScot Leads the Way Curing Diseases with the Power of Nucleic Acid-based Drugs: A Promising Growth Forecast for 2023-2029 - KaleidoScot Leads the Way. With the advancements in medical science, a promising new approach of curing diseases with nucleic acid-based drugs have emerged. One of the leading players in this field, KaleidoScot is paving the way for a brighter future for healthcare. In this article, we will explore the benefits of nucleic acid-based drugs and the potential growth forecast for the field in the coming years. Introduction Over the years, medical research has been striving to find innovative and effective ways to combat diseases and alleviate human suffering. With the rapid evolution of biotechnology and genetic engineering, new horizons have opened up in the field of medicine. One such field that is revolutionizing healthcare is the use of nucleic acid-based drugs for curing diseases. Nucleic acid-based drugs are a class of drugs that target the genetic materials of a cell to bring about a therapeutic effect. These drugs have shown promising results in treating various diseases such as cancer, viral infections, genetic disorders, and autoimmune diseases. One of the leading players in this field is KaleidoScot, a biotech company that is committed to developing novel nucleic acid-based drugs for curing diseases. With promising clinical trials and a strong R&D pipeline, KaleidoScot is leading the way for a brighter future in healthcare. In this article, we will explore the potential benefits of nucleic acid-based drugs, the growth forecast for the field in the coming years and the role of KaleidoScot in advancing the field. Curing Diseases with the Power of Nucleic Acid-based Drugs: What are Nucleic Acid-based Drugs? Nucleic acid-based drugs are a class of drugs that target the genetic materials of a cell to bring about a therapeutic effect. These drugs work by targeting the DNA or RNA of a cell to either silence or activate certain genes. They have the potential to cure diseases at the genetic level, which makes them highly specific and effective. Nucleic acid-based drugs are generally classified into two categories: antisense oligonucleotides (ASOs) and RNA interference (RNAi) therapeutics. ASOs are single-stranded DNA molecules that target specific messenger RNAs (mRNAs) to either degrade or prevent protein synthesis. RNAi therapeutics, on the other hand, use small interfering RNAs (siRNAs) or microRNAs (miRNAs) to target disease-causing genes. Nucleic acid-based drugs have several advantages over traditional drugs. They are highly specific, targetable, and can be designed to target specific genes. They can be used to turn off or turn on genes, which makes them suitable for treating a wide range of diseases. Furthermore, they have low toxicity and fewer side effects compared to traditional drugs. KaleidoScot Leads the Way: The Promising Growth Forecast for 2023-2029 With the increasing demand for better and more effective drugs, the nucleic acid-based drug market is expected to grow at a tremendous pace in the coming years. According to a report by BIS Research, the global nucleic acid-based therapeutics market is expected to surpass $9.37 billion by 2023 and reach $43.57 billion by 2029, growing at a CAGR of 23.79% from 2023-2029. The major factors driving this growth include the rise in the prevalence of genetic disorders, the increasing adoption of personalized medicines, and the advancements in biotechnology and genetic engineering. KaleidoScot, with its top-of-the-line research facilities, expert team of scientists, and innovative approach, is poised to take advantage of this growth and lead the way in the nucleic acid-based drug market. The company is currently engaged in developing novel therapeutics for diseases such as cancer, genetic disorders, and autoimmune diseases. It has a robust pipeline of preclinical and clinical stage products that hold immense promise. The Benefits of Nucleic Acid-based Drugs Nucleic acid-based drugs offer several benefits over traditional drugs. Some of the key benefits include: - Higher Specificity: Nucleic acid-based drugs are highly specific, meaning they can target specific genes or proteins, making them more effective and less toxic compared to traditional drugs. - Personalized Medicine: By targeting specific genes or proteins, nucleic acid-based drugs can be used to develop personalized medicines that are tailored to individual patients' genetic profiles. - Effective Against Previously Incurable Diseases: Nucleic acid-based drugs have shown promising results in treating diseases that were previously considered incurable, such as certain types of cancer and genetic disorders. - Low Immunogenicity: Nucleic acid-based drugs have low immunogenicity, which means that they do not cause an immune response in the body, reducing the risk of adverse reactions. The Potential Applications of Nucleic Acid-based Drugs Nucleic acid-based drugs have immense potential in the field of medicine. Some of the potential applications of nucleic acid-based drugs include: - Treating Genetic Disorders: Nucleic acid-based drugs can be used to target the genetic mutations that cause genetic disorders such as cystic fibrosis, Huntington's disease, and sickle cell anemia. - Treating Cancer: Nucleic acid-based drugs can be used to target oncogenes, which are genes that promote cancer cell growth. - Treating Viral Infections: Nucleic acid-based drugs can be used to target the RNA of the viruses, preventing viral replication and treating viral infections such as HIV and hepatitis C. - Treating Autoimmune Diseases: Nucleic acid-based drugs can be used to target the genes or proteins that are responsible for autoimmune diseases such as lupus and rheumatoid arthritis, reducing inflammation and preventing tissue damage. - Treating Neurodegenerative Diseases: Nucleic acid-based drugs can be used to target the genes that are responsible for neurodegenerative diseases such as Alzheimer's and Parkinson's disease, preventing the progression of these diseases. The Challenges of Nucleic Acid-based Drugs Despite the immense potential of nucleic acid-based drugs, there are several challenges that need to be overcome before they can be used widely. Some of the challenges include: - Delivery: Nucleic acid-based drugs are large molecules and cannot cross the cell membrane on their own, which makes delivery a major challenge. - Stability: Nucleic acid-based drugs are susceptible to degradation by enzymes in the body, which can make them less effective. - Off-Target Effects: Nucleic acid-based drugs can have unintended effects by targeting genes that are not related to the disease being treated, causing adverse reactions. - Cost: Nucleic acid-based drugs are expensive to develop, which can make them prohibitively expensive for many patients. FAQs Q1. How do Nucleic Acid-based Drugs work? A1. Nucleic acid-based drugs work by targeting the DNA or RNA of a cell to either silence or activate certain genes. They have the potential to cure diseases at the genetic level, which makes them highly specific and effective. Q2. What are the benefits of Nucleic Acid-based Drugs? A2. Nucleic acid-based drugs are highly specific, targetable, and can be designed to target specific genes. They can be used to turn off or turn on genes, which makes them suitable for treating a wide range of diseases. Furthermore, they have low toxicity and fewer side effects compared to traditional drugs. Q3. What are the potential applications of Nucleic Acid-based Drugs? A3. Nucleic acid-based drugs have immense potential in the field of medicine. Some of the potential applications of nucleic acid-based drugs include treating genetic disorders, cancer, viral infections, autoimmune diseases, and neurodegenerative diseases. Q4. What are the challenges of Nucleic Acid-based Drugs? A4. Despite the immense potential of nucleic acid-based drugs, there are several challenges that need to be overcome before they can be used widely. Some of the challenges include delivery, stability, off-target effects, and cost. Q5. What is KaleidoScot and its role in the field of Nucleic Acid-based Drugs? A5. KaleidoScot is a biotech company that is committed to developing novel nucleic acid-based drugs for curing diseases. With top-of-the-line research facilities, expert team of scientists, and innovative approach, KaleidoScot is leading the way for a brighter future in healthcare. Q6. What is the growth forecast for the Nucleic Acid-based Therapeutics market? A6. According to a report by BIS Research, the global nucleic acid-based therapeutics market is expected to surpass $9.37 billion by 2023 and reach $43.57 billion by 2029, growing at a CAGR of 23.79% from 2023-2029. Conclusion In conclusion, the emergence of nucleic acid-based drugs has opened up new avenues in the field of medicine. They offer the potential to cure diseases at the genetic level, providing a highly specific and effective approach to healthcare. With a promising growth forecast for the field in the coming years, companies like KaleidoScot are leading the way for a brighter future in healthcare. However, there are several challenges that need to be overcome before nucleic acid-based drugs can be used widely. Research in this field must continue to explore new ways of delivering these drugs effectively, improving their stability, and reducing their cost. As the field progresses and the challenges are overcome, nucleic acid-based drugs have the potential to revolutionize healthcare and cure diseases that were once thought to be incurable. #BUSINESS Read the full article

[technolgy0411]

RNAi Therapeutics Market in Global : Current and the Future Trends

An exhaustive evaluation of restrains included in Antisense and RNAi Therapeutics Market report portrays dissimilarity to drivers and hence, gives room for tactical planning. Characteristics that overshadow market progress are as essential as they can be understood to advance different bends for getting hold of lucrative scenarios that are existing in this ever-growing market. Furthermore, insights into the key specialist’s opinions have been well-thought-out to understand this market better.

The study elaborates growth rate of the Antisense and RNAi Therapeutics Market supported and analysed after exhaustive and reliable company profile analysis. The study offers an in-depth investigation, market size, share, insights, evaluation for developing segment and numerous other important market characteristic in the Antisense and RNAi Therapeutics Market industry.

The Prominent/Emerging Players in the Antisense and RNAi Therapeutics Market includes:

Alnylam Pharmaceuticals

Benitec Biopharma Ltd.

Quark Pharmaceuticals

Ionis Pharmaceuticals

Astellas Pharma Inc

Marina Biosciences

Sanofi S

Dicerna Pharmaceuticals

Tekmira Pharmaceuticals

Merck

The global Antisense and RNAi Therapeutics Market segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antisense and RNAi Therapeutics Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2022-2028.

Antisense and RNAi Therapeutics Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The report currently provides detailed insights on trends, market share, market size, market value, and trading volume. The global Antisense and RNAi Therapeutics Market report provides a comprehensive analysis of COVID-19 infections and how it has impacted market growth. This study explains the future opportunities for market participants. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory.

Research objectives:

To study and analyze the global Antisense and RNAi Therapeutics Market size by key regions/countries, product type and application, history data from 2018 to 2020, and forecast to 2028. To understand the structure of Antisense and RNAi Therapeutics Market by identifying its various sub segments. Focuses on the key global Antisense and RNAi Therapeutics Market players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Antisense and RNAi Therapeutics Market with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the size of Antisense and RNAi Therapeutics Market submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents: Antisense and RNAi Therapeutics Market

Part 1: Overview of Antisense and RNAi Therapeutics Market Part 2: Antisense and RNAi Therapeutics Market Carts: Global Market Status and Forecast by Regions Part 3: Global Market Status and Forecast by Types Part 4: Global Market Status and Forecast by Downstream Industry Part 5: Market Driving Factor Analysis Part 6: Market Competition Status by Major Manufacturers Part 7: Major Manufacturers Introduction and Market Data Part 8: Upstream and Downstream Market Analysis Part 9: Cost and Gross Margin Analysis Part 10: Marketing Status Analysis Part 11: Market Report Conclusion Part 12: Antisense and RNAi Therapeutics Market: Research Methodology and Reference

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

[sdki-blogs-market-news]

Global Nucleic Acid Therapeutics Market : Market Insights & Market Forecast with Potential Impact of COVID-19 (2020-2024)

The global nucleic acid therapeutics market is expected to record a value of US$7.23 billion in 2024, increasing at a CAGR of 33.3%, for the duration spanning 2020-2024. The factors such as rising incidences of new cancer cases, rising penetration of gene therapy, increasing pharmaceutical R&D spending, rise in prevalence of diabetes, upsurge in healthcare expenditures and rapid advances in nucleic acid technologies for diagnostics would drive the growth of the market.

Fill This Form And Get The Sample Copy of This Report -  https://www.sdki.jp/sample-request-62299 "Final Report will cover the full impact of analysis of COVID-19 on this industry (Global Nucleic Acid Therapeutics Market)."

However, the market growth would be challenged by the challenge of delivering nucleic acid therapeutics, development hurdles for RNAi therapeutics and legal regulations. A few notable trends may include, accelerating growth rates of infectious diseases, progress in pharmaceutical and biotech merger & acquisition, growth in government spending on healthcare and development of nucleic acid therapeutics.

The global nucleic acid therapeutics market

holds a very lucrative scope as such class of compounds have emerged in recent years to yield extremely promising candidates for drug therapy to a wide range of diseases.

Based on application, nucleic acid therapeutics are widely used for the treatment of mono-genetic disorders and multi-genetic disorders. The high prevalence of various monogenetic diseases is leading to the rising application of various nucleic acid therapeutics, which is likely to help in its market growth in future.

Fill This Form And Get The Sample Copy of This Report -  

https://www.sdki.jp/sample-request-62299

"Final Report will cover the full impact of analysis of COVID-19 on this industry (Global Nucleic Acid Therapeutics Market)."

Scope of the report:

The report provides a comprehensive analysis of the global nucleic acid therapeutics market.

The major regional markets (Americas, Europe, Asia-Pacific and Middle East & Africa) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Benitec Biopharma, WAVE Life Sciences, Vir Biotechnology and Protagonist Therapeutics) are also presented in detail.

- Table Content

1. Overview

1.1 Introduction

1.2 Difference Between DNA and RNA

1.3 Nucleoside, Nucleotide & Nucleic Acid

1.4 Oligonucleotides

1.5 Comparison of ASO and siRNA Mechanisms

1.6 Nucleic Acid as Therapeutics

1.7 Categories of Nucleic Acid Therapeutics

1.8 Nucleic Acid Therapeutics in Gene Therapy

2. Impact of COVID-19

2.1 Rise in COVID-19 Testing

2.2 Growth in COVID-19 R&D Funding

2.3 Nucleic Acid Vaccines for COVID-19

2.4 Oligonucleotides and COVID-19 Pandemic

3. Global Nucleic Acid Therapeutics Market Analysis

3.1 Global Nucleic Acid Therapeutics Market by Value

3.2 Global Nucleic Acid Therapeutics Market Forecast by Value

3.3 Global Nucleic Acid Therapeutics Market Value by Application

3.3.1 Global Mono Genetic Nucleic Acid Therapeutics Market by Value

3.3.2 Global Mono Genetic Nucleic Acid Therapeutics Market Forecast by Value

3.3.3 Global Multi Genetic Nucleic Acid Therapeutics Market by Value

3.3.4 Global Multi Genetic Nucleic Acid Therapeutics Market Forecast by Value

4. Global Oligonucleotide Therapeutics Market Analysis

4.1 Global Oligonucleotide Therapeutics Market by Value

4.2 Global Oligonucleotide Therapeutics Market Forecast by Value

4.3 Global Oligonucleotide Therapeutics Market Value by Drugs Class

4.3.1 Global ASO (Antisense Oligonucleotide) Therapeutics Market by Value

4.3.2 Global ASO (Antisense Oligonucleotide) Therapeutics Market Forecast by Value

4.3.3 Global SiRNA (Small interfering RNA) Therapeutics Market Forecast by Value

4.4 Global Oligonucleotide Therapeutics Market Value by Regions

5. Regional Oligonucleotide Therapeutics Market Analysis

5.1 Americas

5.1.1 Americas Oligonucleotide Therapeutics Market Forecast by Value

5.2 Europe

5.2.1 Europe Oligonucleotide Therapeutics Market Forecast by Value

5.3 Asia Pacific

5.3.1 Asia Pacific Oligonucleotide Therapeutics Market Forecast by Value

5.4 Middle East & Africa

5.4.1 Middle East & Africa Oligonucleotide Therapeutics Market Forecast by Value

[marketresearchandreports-blog]

Antisense And RNAi Therapeutics Market Size Was Estimated At USD 945.8 Million In 2016 And Is Expected To Witness A CAGR Of 8.6% From 2018 To 2025: Grand View Research, Inc.

Antisense And RNAi Therapeutics Market Size Was Estimated At USD 945.8 Million In 2016 And Is Expected To Witness A CAGR Of 8.6% From 2018 To 2025: Grand View Research, Inc.

The global antisense and RNAi therapeutics market size is expected to reach USD 1.81 billion by 2025, according to a new report by Grand View Research, Inc., recording an 8.6% CAGR during the forecast period. Rising instances of external funding to conduct clinical studies pertaining to introduction of novel drug moieties plays a vital role in the process of new product development. This fuels…

[marketerefforts]

Oligonucleotide Synthesis Market 2023 | Business Opportunity, Growth Strategies & Forecast Report By 2028

The Oligonucleotide Synthesis Market Report, in its latest update, highlights the significant impacts and the recent strategical changes under the present socio-economic scenario. The Oligonucleotide Synthesis industry growth avenues are deeply supported by exhaustive research by the top analysts of the industry. The report starts with the executive summary, followed by a value chain and marketing channels study. The report then estimates the CAGR and market revenue of the Global and regional segments.

Base Year: 2021

Estimated Year: 2022

Forecast Till: 2023 to 2028

The report classifies the market into different segments based on type and product. These segments are studied in detail, incorporating the market estimates and forecasts at regional and country levels. The segment analysis is helpful in understanding the growth areas and potential opportunities of the market.

Get | Download FREE Sample Report of Global Oligonucleotide Synthesis Market @ https://www.decisiondatabases.com/contact/download-sample-17937

A special section is dedicated to the analysis of the impact of the COVID-19 pandemic on the growth of the Oligonucleotide Synthesis market.  The impact is closely studied in terms of production, import, export, and supply.

The report covers the complete competitive landscape of the Worldwide Oligonucleotide Synthesis market with company profiles of key players such as:

Agilent Technologies, Inc.

Bioautomation Corporation

Eurofins Genomics

Eurogentec S.A.

General Electric Company

Integrated DNA Technologies, Inc.

LGC Biosearch Technologies, Inc.

Merck KGaA

Nitto Denko Avecia Inc.

Thermo Fisher Scientific Inc.

Want to add more Company Profiles to the Report? Write your Customized Requirements to us @ https://www.decisiondatabases.com/contact/get-custom-research-17937

Oligonucleotide Synthesis Market Analysis by Product & Service:

Products

Primers

Probes

Large-Scale Synthesis Oligos

Intermediate-Scale Synthesis Oligonucleotides

Linkers And Adaptors

Services

Custom Oligonucleotides

Pre-Designed Oligonucleotides

Reagents

Equipment

Oligonucleotide Synthesis Market Analysis by Application:

Research

PCR

QPCR

Sequencing

Gene Synthesis

Other

Diagnostics

Therapeutics

Rnai

Nucleic Acid Aptamers

DNA/Antisense Oligos

Immunotherapy

Oligonucleotide Synthesis Market Analysis by End-User:

Academic Research Institutes

Pharmaceutical And Biotechnology Companies

Diagnostic Laboratories

Other

Oligonucleotide Synthesis Market Analysis by Geography:

North America (USA, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Australia, South-East Asia, Rest of Asia-Pacific)

Latin America (Brazil, Argentina, Peru, Chile, Rest of Latin America)

The Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa, Rest of the Middle East and Africa)

Key questions answered in the report:

 What is the expected growth of the Oligonucleotide Synthesis market between 2023 to 2028?

Which application and type segment holds the maximum share in the Global Oligonucleotide Synthesis market?

Which regional Oligonucleotide Synthesis market shows the highest growth CAGR between 2023 to 2028?

What are the opportunities and challenges currently faced by the Oligonucleotide Synthesis market?

Who are the leading market players and what are their Strengths, Weakness, Opportunities, and Threats (SWOT)?

What business strategies are the competitors considering to stay in the Oligonucleotide Synthesis market?

Purchase the Complete Global Oligonucleotide Synthesis Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-17937

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 90 28 057900 Web: https://www.decisiondatabases.com/

[dbmrmarketnews]

RNA Therapeutics Market Size, Trends, Emerging Market Trends and Forecast by Players and Types By 2027

RNA Therapeutics Market Research Report will give its customers Full Analytical Research, which gives all in-out details about key players like company profile, product portfolio, capacity, price, cost, and revenue for the forecast period of 2020 to 2027. This report presents an in-depth analysis of the RNA Therapeutics market size, share, segments, manufacturers, and technologies, key trends, market drivers, challenges, standardization, deployment models, opportunities, future roadmap, and forecast.

RNA therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of the genetic diseases, neurological disorders and advancement in the biotechnological sector are the factors responsible for the growth of this market

Advancement in the treatment options to target specificity and selectivity drives the growth of RNA therapeutics market. Rapid adoption of newer formulations and novel drug delivery boost up the RNA therapeutics market growth. In addition, approval and launch of RNA therapeutics plays a major role in growth of market in the above forecasted period. Furthermore, special designation from the regulatory authority is one of the significant factors which are expected to drive the market growth.

Download Exclusive Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-rna-therapeutics-market

The RNA therapeutics market is segmented on the basis of technologies, application, route of administration and end-users.

Based on technologies, the RNA therapeutics market is segmented into enabling technologies, enabled technologies. The enabling technologies are further categorized into microarray, labeling, purification, inhibition and others. The enabled technologies are further bifurcated into RNA interference (RNAi) technologies and RNA antisense technologies.

The application segment for RNA therapeutics market includes cardiovascular, oncology, infections, immunology, metabolic disorders and others.

On the basis of route of administration, RNA therapeutics market is segmented into oral, subcutaneous, intravenous, and intramuscular and others.

Based on end-user, the substance abuse and addiction treatment market is segmented into hospitals, research organization, specialty clinics, diagnostic laboratory and others

The research provides answers to the following key questions:

What is the estimated growth rate of the market for the forecast period 2020–2027? What will be the market size during the estimated period?

What are the key driving forces responsible for shaping the fate of the RNA Therapeutics market during the forecast period?

Who are the major market vendors and what are the winning strategies that have helped them occupy a strong foothold in the RNA Therapeutics market?

What are the prominent market trends influencing the development of the RNA Therapeutics market across different regions?

What are the major threats and challenges likely to act as a barrier in the growth of the RNA Therapeutics market?

What are the major opportunities the market leaders can rely on to gain success and profitability? 

To Know More Details, Visit in Depth Study Report @ https://www.databridgemarketresearch.com/reports/global-rna-therapeutics-market

The RNA Therapeutics Market Report Addresses the Following Queries:

What is the estimated size of the RNA Therapeutics market by 2027?

Which segment accounted or a large share of the RNA Therapeutics market in the past?

Which segment is expected to account the largest market share by 2027?

Which governing bodies have approved the use of RNA Therapeutics?

Which region accounts for a dominant share of the RNA Therapeutics market?

Which region is anticipated to create lucrative opportunities in the RNA Therapeutics market? 

Some extract from Table of Contents

Overview of Global RNA Therapeutics Market

RNA Therapeutics Size (Sales Volume) Comparison by Type (2020-2027)

RNA Therapeutics Size (Consumption) and Market Share Comparison by Application (2020-2027)

RNA Therapeutics Size (Value) Comparison by Region (2020-2027)

RNA Therapeutics Sales, Revenue and Growth Rate (2020-2027)

RNA Therapeutics Competitive Situation and Trends

Players/Suppliers High Performance Pigments Manufacturing Base Distribution, Sales Area, Product Type [Head-Mounted Displays, Assisted Reality Glasses, Mixed Reality Holographic Displays, Smart Helmets]

Analyze competitors, including all important parameters of RNA Therapeutics

Global RNA Therapeutics Manufacturing Cost Analysis

Marketing Strategy Analysis, Research Conclusion

Check Complete Table of Contents with List of Table and Figures @ https://www.databridgemarketresearch.com/toc/?dbmr=global-rna-therapeutics-market

In conclusion, the Global RNA Therapeutics Market Report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Our Reports Will Help Clients Solve the Following Issues: –

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and Insights help our clients identify compatible business partners.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, LATAM, Europe or Southeast Asia or Just Eastern Asia.

The major players covered in the RNA therapeutics market are Quark, Alnylam Pharmaceuticals, Inc Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics, Cenix BioScience, Sirnaomics, CureVac AG, BioNTech SE, Arrowhead Pharmaceuticals, Inc, Arbutus Biopharma, Marina Biotech, Inc and among others.

Browse Related Reports@

Over the Counter (OTC) Drugs Market                                  

Pelvic Cancer Drug Market                                         

Microsurgery Market                                    

Xerostomia Therapeutics Market                                            

[vicky8588]

RNAi Therapeutics Market

Market Overview

The Global "RNAi Therapeutics Market" is estimated to reach at a high CAGR during the forecast period (2021-2028).

 RNA therapeutics are a novel class of medications based on ribonucleic acid (RNA). RNA interference is a biological process in which target mRNA molecules are neutralized, and RNA molecules are observed to inhibit gene expression or translation. Furthermore, RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequential-specific inhibition of genetic expression.

Download Free Samples @ https://www.datamintelligence.com/download-sample/rnai-therapeutics-market

 Market Dynamics

The global RNAi therapeutics market growth is driven by the increasing incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases, increasing collaborative activities between drug distribution companies and contract research organizations (CROs).

 Increasing collaborative activities boosting the growth of the RNAi therapeutics market

 The increasing collaborative activities between drug distribution companies and contract research organizations (CROs) contribute to RNAi therapeutics market growth. On June 21, 2021, Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and license agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. This collaboration with Horizon also represents a further expansion of Arrowhead Pharmaceuticals' rapidly growing pipeline of investigational RNAi therapeutics that utilize Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform.” In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) initiated a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to the treatment of Hepatitis B viral infection. And also, one more collaboration by Ionis pharmaceuticals with Akcea Therapeutics has led to the approval of the world’s first antisense-based molecule “Tegsdi” by the FDA and the European Commission in 2018.

 Moreover, despite these factors, it has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies. Quark, Alnylam, and silence therapeutics are other major players in this market with a strong research pipeline in RNAi therapeutics. For instance, Silence therapeutics mRNAi GOLD platform is designed to deliver gene-silencing medicine to targeted liver cells in the body by combining siRNA molecules with chemical address tags called GaINAc, a naturally occurring sugar that attaches specifically to liver cells. These RNAi molecules can then enter liver cells and silence targeted; disease-associated genes expressed in the liver.

 In May 2021, Silence therapeutics completed its phase 1 study of SLN124, which is a gene silencing therapy for treating rare iron-loading anemia conditions, thalassemia, and myelodysplastic syndrome (MDS) patients.

 High investment and strict regulations are likely to hamper the market growth

 In recent years, there has been a decline in FDA drug approval rates. Receiving FDA approval for a new drug has become extremely challenging. It approved less than half the number of new drugs in 2016 (19 so far) when compared to 2015 (45 total) and 2014 (41 total). Hence, despite the large investments, there has been a decline in innovative drugs manufactured. FDA explains manufacturing standards and other complying issues as the major reasons for this declining trend. This can impede the growth of the RNAi therapeutics, especially since the miRNAs and siRNAs fall into the relatively new field of genetic medicine, wherein they may require more intensified clinical trials. The highly extensive clinical trials effectively result in low approval rates of drugs. This would mean that the stringent guidelines will be a major restraint on the growth of the market.

 COVID-19 Impact Analysis

There has been continuous progress in understanding diseases at the genomic and molecular levels, and various companies are deploying resources to test these diseases to leverage opportunities that fuel the market opportunities. For instance, in August 2020, GeneDx Inc., a subsidiary of BioReference Laboratories Inc., and OPKO Health agreed with Pediatrix Medical Group to offer state-of-the-art, next-generation genomic sequencing to support the clinical diagnosis of rare diseases for neonatal intensive care units.

 RNAi has been widely accepted in providing the highest possible resolution information about COVD-19 and is believed to potentially transform COVID-19 infectious disease management.

 For instance, in earlier 2020, the UK government launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. The COVID-19 Genomics UK Consortium (COG-UK) comprises the NHS (National Health Service), public health agencies, the Wellcome Sanger Institute, and several academic institutions, helping in creating funds and developing diagnostics and treatment.

 Segment Analysis

The oncology segment is expected to hold the largest share in this market segment

 According to the World Health Organization, cancer is the second leading cause of death globally and responsible for 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. The number of new cases is expected to increase by about 70% over the next two decades. Also, recent advancements, such as the development of small interfering RNA (siRNA) tolerant to nucleases and non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this obstacle and facilitate the clinical use of RNAi-based therapeutics in the treatment of cancer.

 Substantial pipeline for cancer therapies by companies and institutes such as Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, AstraZeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. are expected to drive the market. In addition, many companies have invested in R&D for nanocarriers to deliver oligonucleotides for cancer treatment, which is expected to contribute to the oncology segment.

 Geographical Analysis

North America region holds the largest market share of the global RNAi therapeutics market

 The U.S. has several RNAi therapies that are in the developmental pipeline. Many biotechnology companies have invested heavily in RNAi therapeutic development. Many pharmaceutical developers have entered into cooperation agreements or licensing agreements with many small companies to capitalize on the expected growth in revenue during the forecast period of this market. For example, AstraZeneca’s deal with Ionis Pharmaceuticals is majorly investing heavily in RNA-interference technology. Also, in September 2018, Delos Capital developed MRNA-based drugs for chemotherapy-resistant cancer. Curamir Therapeutics received initial financial support. With the help of these new companies, acquisitions, and new inventions, North America is dominating the market.

View Full Report @ https://www.datamintelligence.com/research-report/rnai-therapeutics-market

 Competitive Landscape

The global RNAi therapeutics market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Silence Therapeutics, Arrowhead Pharmaceuticals, Inc, Sanofi, GlaxoSmithKline Plc, Arbutus Biopharma Corporation, Benitec Biopharma, Thermo Fisher Scientific Inc and Sirnaomics, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, on April 8, 2019, Regeneron Pharmaceuticals, Inc and Alnylam Pharmaceuticals, Inc announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise and will build on Alnylam's recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS.

 Global RNAi Therapeutics Market – Key Companies to Watch

Alnylam Pharmaceuticals, Inc

 Overview: Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. It operates in 19 countries with more than 1K employees. It conducts its operations in RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of medicines. In 2018, its first medicine, ONPATTRO (patisiran), became the world’s first approved RNAi therapeutic. They are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

 Product Portfolio: It includes products like ONPATTRO (patisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran).

 Key Developments: Alnylam Pharmaceuticals, ALN-HBV02 is a subcutaneously administered, investigational RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of chronic HBV infection. ALN-HBV02 is designed to inhibit the expression of all HBV proteins, including hepatitis B surface antigen (HBsAg) is under Phase 3 trials. ALN-HBV02 utilizes the Enhanced Stabilization Chemistry-Plus (ESC+)-GalNAc delivery platform.

 Global RNAi Therapeutics Market – Notable Developments

In November 2017, Arcturus Therapeutics merged with Alcobra Ltd.

 In October 2017, Alnylam and Vir formed a strategic alliance to advance RNAi therapeutics for infectious diseases.

 On February 26, 2020, Alnylam Pharmaceuticals, Inc. RNAi Therapeutics, a leading company has announced that the Brazilian Health Regulatory Agency (ANVISA) has approved ONPATTRO for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

 June 2020, OliX Pharmaceuticals agreed with LGC Biosarch Technology to accelerate the production of asymmetric siRNA for the treatment of subretinal fibrosis and wet macular degeneration.

For Enquiry @ https://www.datamintelligence.com/enquiry/rnai-therapeutics-market

 About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

 For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com

[unabashedcollectivepizza]

Synthetic siRNA Market Trend, Opportunities, Revenue, Future Scope and Forecast 2027

Synthetic siRNA Market Overview:

Synthetic siRNA are also known as short interfering RNA, which is a type of non-coding double stranded RNA of 20-23 nucleotide base pairs in length. It is a powerful tool used for modulating gene expression by RNA interference (RNAi).siRNAs consist of two RNA strands, an antisense (or guide) strand and a sense (or passenger) strand, which form a duplex 19 to 25 bp in length with 3' dinucleotide overhangs.

The primary goal of the Synthetic siRNA market research is to provide detailed information on market opportunities that are assisting in the transformation of global Synthetic siRNA enterprise. Report  provide projected growth rates along with the compound annual growth rate (CAGR) for forecasted period to enable readers to better understand the monitoring and assessment of the global Synthetic siRNA market, as well as to discover lucrative opportunities in the market.

Request for free sample:

https://www.maximizemarketresearch.com/request-sample/88214

Market Scope:

Global Synthetic siRNA Market, by Region:

• North America • Europe • South America • MEA • APAC

Maximize Market Research, report provides a unique research approach to conduct detailed research on the global Synthetic siRNA market and make conclusions on the market's future growth factors. Primary and secondary research methodologies are combined in the research approach to assure the authenticity and validity of the conclusions in this report.

The report discusses the Synthetic siRNA market's drivers, restraints, opportunities, and challenges. The research helps to identify the market growth drivers and determining how to utilize these factors as strengths. Restraints can assist readers in identifying traits that are restricting the Synthetic siRNA market, as well as reducing them before they become an issue.  This will assist readers in comprehending the aspects that will influence your ability to capitalise on possibilities.

Segmentation:

Get more Report Details

https://www.maximizemarketresearch.com/request-sample/88214

Key Players:

• Thermo Fisher Scientific Inc. • Bioneer • Dharmacon (ThermoFisher) • Invitrogen • Integrated DNA Technologies • MWG Biotech • OligoEngine • Proligo (Sigma) • Qiagen • AstraZeneca • Ionis pharmaceuticals • Alnylam Pharmaceuticals • Arcturus Therapeutics • Dicerna Pharmaceuticals

Regional Analysis:

Geographically, Synthetic siRNA market report is segmented into several key regions are as follows,

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

North America (the United States, Mexico, and Canada.)

South America (Brazil etc.)

The Middle East and Africa (GCC Countries and Egypt.)

Furthermore, the study covers market size, growth rate, import and export, as well as country-level analysis, integrating the demand and supply forces of the Synthetic siRNA market in these countries, which are impacting market growth.

COVID-19 Impact Analysis on Synthetic siRNA Market:

COVID-19's global influence on the Synthetic siRNA market was examined in this research. During this crisis, the report examines the Synthetic siRNA market's alternatives, demanding conditions, and difficult possibilities in detail. In terms of funding and market expansion, the paper briefly examines the COVID-19's merits and limitations. The study also contains a set of concepts that should aid readers in developing and planning company strategies.

The report considers consultations to overcome past disruptions and foresees potential ones in order to improve preparation. Businesses can use the frameworks to design their strategic alignments in order to recover from such disruptive trends. Maximize Market Research analysts can also assist readers in breaking down a complex circumstance and bringing resiliency to a situation that is uncertain.

About Us:

Maximize Market Research provides B2B and B2C research on 12000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defence and other manufacturing sectors.

Contact Us:

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Navale IT Park Phase 2,

Pune Bangalore Highway,

Narhe, Pune, Maharashtra 411041, India.

Email: sales@maximizemarketresearch.com

Phone No.: +91 20 6630 3320

Website: www.maximizemarketresearch.com

[marketresearchtrendsblog]

RNA Therapy Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

The report on the global RNA therapy market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global RNA therapy market to grow with a CAGR of 8.5% over the forecast period from 2019-2025. The study on RNA therapy market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025. The report on RNA therapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global RNA therapy market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-103805 Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global RNA therapy market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider. Report Findings 1) Drivers ? Rising genetic diseases, neurological disorders and viral infections ? Advancement in the sectors of molecular technology, nanotechnology and biology 2) Restraints ? High cost associated with detection kits and analytical instruments 3) Opportunities ? RNA therapy provides number of advantages over chemotherapy Research Methodology A) Primary Research Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include 1. Key Opinion Leaders associated with Infinium Global Research 2. Internal and External subject matter experts 3. Professionals and participants from the industry Our primary research respondents typically include 1. Executives working with leading companies in the market under review 2. Product/brand/marketing managers 3. CXO level executives 4. Regional/zonal/ country managers 5. Vice President level executives. B) Secondary Research Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources. The secondary sources of the data typically include 1. Company reports and publications 2. Government/institutional publications 3. Trade and associations journals 4. Databases such as WTO, OECD, World Bank, and among others. 5. Websites and publications by research agencies Segment Covered The global RNA therapy market is segmented on the basis of technology, and application. The Global RNA Therapy Market by Technology ? Enabling Technologies ? Enabled Technologies ? RNA Antisense Technologies ? RNA Interference (RNAi) Technologies The Global RNA Therapy Market by Application ? Kidney Diseases ? Cardiovascular ? Infectious Diseases ? Oncology ? Metabolic Disorders ? Other Applications Company Profiles The companies covered in the report include ? Silence Therapeutics ? Cenix BioScience GmbH ? Sanofi Genzyme ? Benitec Biopharma Ltd ? Arbutus Biopharma Corporation ? DiceRNA Pharmaceuticals ? Alnylam Pharmaceuticals Inc. ? Quark Pharmaceuticals ? Other Companies What does this report deliver? 1. Comprehensive analysis of the global as well as regional markets of the RNA therapy market. 2. Complete coverage of all the segments in the RNA therapy market to analyze the trends, developments in the global market and forecast of market size up to 2025. 3. Comprehensive analysis of the companies operating in the global RNA therapy market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company. 4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count Email: sales@sdki.jp Tel: + 81 3 45720790

[marketresearchandreports-blog]

Antisense And RNAi Therapeutics market Size Was Valued At USD 878.7 Million In 2014 And Is Anticipated To Reach $4.58 Billion By 2022: Grand View Research, Inc.

The global antisense and RNAi therapeutics market is anticipated to reach USD 4.58 billion by 2022, according to a new report by Grand View Research, Inc. Technological development in the drug delivery technology based on liposome and nano biotechnology is expected to provide the market with a high potential to grow due to enhancement in the adoption of gene silencing therapeutic product models.…

[market-insider]

Antisense & RNAi Therapeutics Market Product Developments and Growth Forecast

The global antisense & RNAi therapeutics market size is expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%, according to a new report by Grand View Research, Inc. Development in biological vectors and nanotechnology and rising external funding to conduct clinical studies pertaining to introduction of novel drug moieties play a vital role in the process of product development and fuel growth in this market.

Multinational healthcare establishments promote awareness and aid in finding novel therapies for treatment of different disorders. Private institutes such as California Institute of Regenerative Medicine and ALS Association that are involved in conducting trials by funding the research institutes and pharmaceutical organizations are expected to fuel sector growth significantly. Moreover, government initiatives for speeding the development of drug delivery platforms in order to reduce the disease burden are attributive for industrial growth.

Antisense & RNAi therapeutics services are applicable in treatment of several range of diseases that target the nucleic acid and affect cell growth cycle. miRNA is attracting considerable interest in its ability to restore gene expression and correct protein production thereby influencing industrial progress. Developments that involve research for utilization of different routes to deliver the desired effect of candidate moiety before its removal from blood are anticipated to fuel sector growth.

However, challenges associated with the drug delivery are expected to impede growth to certain extent. Delivery technologies that enable mitigation of the off-target effects and undesirable immunological stimulation need to be introduced to reduce the effect of restraining factors.

For More Details or Sample Copy please visit link @: https://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market